Status:
COMPLETED
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This study is to evaluate long-term safety and efficacy after concomitant administration of ASP1941 and α-glucosidase inhibitor in Japanese patients with type 2 diabetes mellitus.
Detailed Description
This is a 52-week multi-center study in subjects with type 2 diabetes mellitus who have inadequate glycemic control on an α-Glucosidase Inhibitor alone. Dosage may be increased during the treatment pe...
Eligibility Criteria
Inclusion
- Type 2 diabetic patients receiving with α-glucosidase inhibitor mono-therapy for at least 4 weeks
- HbA1c value between 6.5 and 9.5%
- Body Mass Index (BMI) 20.0 - 45.0 kg/m2
Exclusion
- Type 1 diabetes mellitus patients
- Serum creatinine \> upper limit of normal
- Proteinuria (albumin/creatinine ratio \> 300mg/g)
- Dysuria and/or urinary tract infection, genital infection
- Significant renal, hepatic or cardiovascular diseases
- Severe gastrointestinal diseases
Key Trial Info
Start Date :
October 21 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 25 2012
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT01242202
Start Date
October 21 2010
End Date
May 25 2012
Last Update
May 30 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Chūbu, Japan
2
Hokkaido, Japan
3
Kansai, Japan
4
Kantou, Japan